These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 33469677)

  • 1. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
    Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
    Front Immunol; 2021; 12():699895. PubMed ID: 34367161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
    Mu Y; Guan X
    Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT as an emerging immune checkpoint.
    Harjunpää H; Guillerey C
    Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor intrinsic and extrinsic immune functions of CD155.
    O'Donnell JS; Madore J; Li XY; Smyth MJ
    Semin Cancer Biol; 2020 Oct; 65():189-196. PubMed ID: 31883911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT enhances CD4
    Chen F; Xu Y; Chen Y; Shan S
    Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients.
    Li C; Liu H; Duan Z
    BMC Immunol; 2024 Feb; 25(1):12. PubMed ID: 38326745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
    Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
    Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Advance of Immune Checkpoint Molecule TIGIT in Hematological Malignancies--Review].
    Lu H; Wang HF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):993-997. PubMed ID: 34105506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.